HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICMAD Beefs Up Lobbying To Deter 'Wrong Decision' In Congress

This article was originally published in The Rose Sheet

Executive Summary

Pam Busiek, head of the Independent Cosmetic Manufacturers and Distributors, discusses the trade group's ongoing work in Washington where multiple, differently sized bills for updating cosmetics regulations are under consideration. Notably, ICMAD's roster of advocates now includes former FDA Cosmetics Director John Bailey.

You may also be interested in...

‘California’s A Problem,’ But Prop 65 Preemption For Cosmetics Could Be Out Of Reach

California is the poster child for regulation in excess of federal requirements, but the biggest challenges it poses to cosmetics companies will be difficult – if not impossible – to resolve via “national uniformity” provisions in legislation before Congress.

PCPC Wants Cosmetics Reform Passed Before Threatened 'Blue Wave'

At the trade group's annual meeting in Palm Beach, Fla., leadership emphasized the importance of pushing cosmetics reform legislation over the finish line before November midterm elections. PCPC's support of a bipartisan proposal released by the Senate Health Committee largely hinges on preemption, the group indicated.

ICMAD Focuses On Education With Membership Up 26% In Five Years

Independent Cosmetic Manufacturers and Distributors membership is up 26% since 2012, reflecting the trade group’s education offerings for members, program benefits and advocacy, according to President and CEO Pamela Busiek.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts